Fact CheckerSign in

NCT07072676Enrolling by invitation

The Use of Assistive Gait Devices Can Reduce the Risk of Falls in Patients With Neuromuscular Diseases Following a Training Period.

Source: ClinicalTrials.gov · Last updated 18 Jul 2025 · Not updated for over 12 months - ask the site whether it is still open

Brief summary (registry, in English)

The planned project is an intervention study to assess the risk of falling after adaptation of an assistive gait devices in patients with the following neuromuscular diseases: Inclusion body myositis, myotonic dystrophy, limb girdle and facioscapulohumeral muscular dystrophies, Pompe disease, Lambert-Eaton syndrome, myasthenia gravis, spinal muscular atrophy, Guillain-Barré syndrome, chronic inflammatory demyelinating polyradiculoneuropathy, Friedreich's ataxia and hereditary motor and sensory neuropathy. The primary aim is to assess the risk of falling after a suitable assistive gait device has been provided with an adaptation phase through training. The data should help to improve the provision of aids for patients with neuromuscular diseases. This should have a positive effect on the risk of falling and thus improve quality of life and reduce mortality and morbidity. To achieve these goals, a one-week intervention with training sessions on handling, balance and coordination as well as fall prevention will becarried out after the patient has been fitted with a suitable assistive gait device. The interventions will be embedded in the inpatient rehabilitation programme. The functional gait and balance tests 'Timed Up and Go', '10 metre walk test', '6-minute walk test' and 'Dynamic Gait Index' will be recorded additionally. The Falls Efficacy Scale International questionnaire will be utilised to evaluate the risk of falling, while the Quebec User Evaluation of Satisfaction with Assistive Technology questionnaire will be employed to ascertain satisfaction with the assistive devices. The study is scheduled to run for a period of 14 days, during which participants will undergo three functional walking and balance tests. As part of the inpatient rehabilitation programme, participants will undergo a week-long period of rehabilitation without assistive technology, followed by a subsequent week of rehabilitation with adapted assistive technology.

Status (registry)
Enrolling by invitation
Study type
Interventional
Enrollment
30 (estimated)
First submitted
27 Jun 2025
Start date
1 Sept 2025
Primary completion date
1 May 2027
Lead sponsor
LMU Klinikum
NCT number
NCT07072676

What you commit to

  • Study type: Interventional
  • Planned participants: 30
  • From 1 Sept 2025 to the primary completion date, 1 May 2027
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • The patient had knee, hip or back surgery in the last three months.

Other illness

  • Patients suffering from polyneuropathy without a diagnosis of inflammatory autoimmune neuropathy.

Other

  • The Patients scored more than 23 points on the falls efficacy Scale-International
  • The Patients are unable to walk at least ten metres without assistance,

Who the study is looking for

  • The Patients with sufficient cognitive and communicative abilities,
  • The Patients with confirmed by the genetic report and/or the final clinical diagnosis.

Age in the registry: 65 years to 65 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Medical Park, Bad Feilnbach, Reithofpark
Coordinator of this site? Confirm its status
Bad FeilnbachGermanyUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.